QIAGEN (QGEN)
(Delayed Data from NYSE)
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Verastem (VSTM) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Walgreens' Pharmacy International Arm Faces Coronavirus Woes
by Zacks Equity Research
Walgreens (WBA) expects the adverse impact of COVID-19 to continue in the fiscal fourth quarter.
Integra (IART) Preliminary Q3 Results Show Recovery in Sales
by Zacks Equity Research
Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.
Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing
by Zacks Equity Research
The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.
Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries
by Zacks Equity Research
Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries
Coronavirus Drives Testing Stocks: Is There Room for More Upside?
by Urmimala Biswas
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
Here's Why You Should Add Globus Medical to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.
LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA
by Urmimala Biswas
According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.
Align Technology Rides on Invisalign Amid Coronavirus Woes
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications
by Zacks Equity Research
Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.
Buy These 5 Low-Beta Stocks to Survive the Choppy Market
by Nilanjan Banerjee
To combat market volatility, create a portfolio of low-beta stocks.
Here's Why Qiagen (QGEN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Qiagen (QGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
LabCorp Coronavirus Test Sales Aid Growth Amid Volume Woes
by Zacks Equity Research
There has been a steady recovery in the Base Business of LabCorp (LH).
Insulet (PODD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.
Thermo Fisher Rides on End Market Growth, Test Revenues
by Zacks Equity Research
Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Hologic (HOLX) Receives EUA for Asymptomatic Coronavirus Testing
by Zacks Equity Research
The FDA approves Hologic's (HOLX) Panther Fusion SARS-CoV-2 assay and pooling protocol to curb the unrelenting spread of coronavirus.
Medtronic, Axonics Patent War Continues for Sacral Neuromodulation (Revised)
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic
by Debanjana Dey
Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.
Blueprint Medicines' Gist Drug Ayvakyt Gets EU Approval
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V mutation.
Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants
by Zacks Equity Research
Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.
Syneos Health Banks on Essential Therapies Amid Coronavirus Woe
by Zacks Equity Research
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
Medtronic Wins Neuromodulation Patent Dispute Against Axonics
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on product launches as well as solid third-quarter of fiscal 2020 results.